Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNOPSYS INC Director's Dealing 2021

Aug 24, 2021

29855_dirs_2021-08-24_c206a3bc-7d4e-4065-85bf-7515d25de25a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNOPSYS INC (SNPS)
CIK: 0000883241
Period of Report: 2021-08-20

Reporting Person: CHAN CHI-FOON (Director, Co-CEO & President)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-20 Common Stock S 12319 $314.9797 Disposed 164515 Direct
2021-08-20 Common Stock M 160899 $60.37 Acquired 325414 Direct
2021-08-20 Common Stock S 160899 $314.9797 Disposed 164515 Direct
2021-08-20 Common Stock M 105424 $90.51 Acquired 269939 Direct
2021-08-20 Common Stock S 105424 $314.9797 Disposed 164515 Direct
2021-08-23 Common Stock M 310 $90.51 Acquired 164825 Direct
2021-08-23 Common Stock S 310 $316.43 Disposed 164515 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-08-20 Non-Qualified Stock Option (right to buy) $60.37 M 160899 Disposed 2023-12-15 Common Stock (160899) Direct
2021-08-20 Non-Qualified Stock Option (right to buy) $90.51 M 105424 Disposed 2024-12-08 Common Stock (105424) Direct
2021-08-23 Non-Qualified Stock Option (right to buy) $90.51 M 310 Disposed 2024-12-08 Common Stock (310) Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: Represents a weighted average sale price per share. These shares were sold in multiple transactions at prices ranging from $310.62 to $317.55. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

F3: 1/4 of the grant becomes exercisable one year after grant date with the remainder becoming exercisable in a series of 12 equal quarterly installments thereafter, subject to continued service through each vesting date.